Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells

American Journal of Physiology - Cell Physiology

Volumn 299, Issue 6, 2010, Pages

  Chacko, Simi M ^a   Ahmed, Shabnam ^a   Selvendiran, Karuppaiyah ^a   Kuppusamy, M Lakshmi ^a   Khan, Mahmood ^a   Kuppusamy, Periannan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cell therapy; Myocardial infarction

Indexed keywords

ANGIOGENIC FACTOR; CASPASE 3; CASPASE 7; CD31 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CONNEXIN 43; CYTOCHROME C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PROTEIN KINASE B; PROTEIN P21; SCATTER FACTOR RECEPTOR; SURVIVIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; HEART MUSCLE CELL; MESENCHYMAL STEM CELL; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CASPASE 3; CASPASE 7; CELL HYPOXIA; CELL LINE; CONNEXIN 43; CYTOCHROMES C; HEART; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICROTUBULE-ASSOCIATED PROTEINS; MYOSIN HEAVY CHAINS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RATS; RECEPTORS, CXCR4; RHO GTP-BINDING PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 78649673599     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00221.2010     Document Type: Article

References (43)

1. Abdollahi H, Harris LJ, Zhang P, McIlhenny S, Srinivas V, Tulenko T, Dimuzio PJ. The role of hypoxia in stem cell differentiation and therapeutics. J Surg Res. In press.
2. Abraham MR, Gerstenblith G. Preconditioning stem cells for cardiovascular disease: an important step forward. Circ Res 100: 447-449, 2007. (Pubitemid 46673252)
3. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177-11182, 1998.
4. Chacko SM, Khan M, Kuppusamy ML, Pandian RP, Varadharaj S, Selvendiran K, Bratasz A, Rivera BK, Kuppusamy P. Myocardial oxygenation and functional recovery in infarct rat hearts transplanted with mesenchymal stem cells. Am J Physiol Heart Circ Physiol 296: H1263-H1273, 2009.
5. Chin SP, Poey AC, Wong CY, Chang SK, Teh W, Mohr TJ, Cheong SK. Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy 12: 31-37, 2010.
6. Chugh AR, Zuba-Surma EK, Dawn B. Bone marrow-derived mesenchymal stems cells and cardiac repair. Minerva Cardioangiol 57: 185-202, 2009.
7. Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 82: 2031-2037, 1993.
8. Cristante AF, Barros-Filho TE, Tatsui N, Mendrone A, Caldas JG, Camargo A, Alexandre A, Teixeira WG, Oliveira RP, Marcon RM. Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. Spinal Cord 47: 733-738, 2009.
9. Csete M. Oxygen in the cultivation of stem cells. Ann NY Acad Sci 1049: 1-8, 2005.
10. Das R, Jahr H, van Osch GJ, Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev 16: 159-168, 2010.
11. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
12. Erwin GS, Crisostomo PR, Wang Y, Wang M, Markel TA, Guzman M, Sando IC, Sharma R, Meldrum DR. Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. J Surg Res 152: 319-324, 2009.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
14. Geng YJ. Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann NY Acad Sci 1010: 687-697, 2003.
15. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20: 661-669, 2006.
16. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 358: 948-953, 2007.
17. Haack-Sorensen M, Bindslev L, Mortensen S, Friis T, Kastrup J. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy 9: 328-337, 2007. (Pubitemid 46993221)
18. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock 33: 24-30, 2010.
19. Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, Kerst G, Muller I. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol 11: 11, 2010.
20. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135: 799-808, 2008.
21. Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J, Prockop DJ. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PloS One 2: e416, 2007.
22. Jin Y, Kato T, Furu M, Nasu A, Kajita Y, Mitsui H, Ueda M, Aoyama T, Nakayama T, Nakamura T, Toguchida J. Mesenchymal stem cells cultured under hypoxia escape from senescence via down-regulation of p16 and extracellular signal regulated kinase. Biochem Biophys Res Commun 391: 1471-1476, 2010.
23. Ju Z, Choudhury AR, Rudolph KL. A dual role of p21 in stem cell aging. Ann NY Acad Sci 1100: 333-344, 2007.
24. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 22: 1003-1012, 2010.
25. Khan M, Kutala VK, Vikram DS, Wisel S, Chacko SM, Kuppusamy ML, Mohan IK, Zweier JL, Kwiatkowski P, Kuppusamy P. Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile function. Am J Physiol Heart Circ Physiol 293: H2129-H2139, 2007.
26. Khan M, Kwiatkowski P, Rivera BK, Kuppusamy P. Oxygen and oxygenation in stem-cell therapy for myocardial infarction. Life Sci 87: 269-274, 2010.
27. Lasala GP, Minguell JJ. Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction. Heart Lung Circ 18: 171-180, 2009.
28. Lin Q, Kim Y, Alarcon RM, Yun Z. Oxygen and cell fate decisions. Gene Regul Syst Bio 2: 43-51, 2008.
29. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond. Circulation 121: 586-613, 2010.
30. Lunde K, Solheim S, Forfang K, Arnesen H, Brinch L, Bjornerheim R, Ragnarsson A, Egeland T, Endresen K, Ilebekk A, Mangschau A, Aakhus S. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol 51: 674-676, 2008.
31. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, Taneera J, Fleischmann BK, Jacobsen SE. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10: 494-501, 2004.
32. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22: 377-384, 2004. (Pubitemid 38736621)
33. Pons J, Huang Y, Arakawa-Hoyt J, Washko D, Takagawa J, Ye J, Grossman W, Su H. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 376: 419-422, 2008.
34. Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen G, Zhao RC. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun 347: 12-21, 2006. (Pubitemid 44040907)
35. Shim WS, Jiang S, Wong P, Tan J, Chua YL, Tan YS, Sin YK, Lim CH, Chua T, Teh M, Liu TC, Sim E. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun 324: 481-488, 2004.
36. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24: 1254-1264, 2006.
37. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J 409: 19-26, 2008.
38. Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 46: 1799-1802, 2005.
39. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93-98, 2002.
40. Von Harsdorf R, Poole-Wilson PA, Dietz R. Regenerative capacity of the myocardium: implications for treatment of heart failure. Lancet 363: 1306-1313, 2004. (Pubitemid 38496496)
41. Wang JA, Chen TL, Jiang J, Shi H, Gui C, Luo RH, Xie XJ, Xiang MX, Zhang X. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Acta Pharmacol Sin 29: 74-82, 2008.
42. Wang JA, He A, Hu X, Jiang Y, Sun Y, Jiang J, Gui C, Wang Y, Chen H. Anoxic preconditioning: a way to enhance the cardioprotection of mesenchymal stem cells. Int J Cardiol 133: 410-412, 2009.
43. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 33: 907-921, 2001.